Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$12.23
-0.9%
$11.91
$10.45
$21.69
$4.32B0.56691,205 shs397,535 shs
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$22.26
+1.1%
$22.72
$18.70
$29.55
$1.06B1.82406,933 shs436,920 shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$78.16
-1.3%
$73.64
$36.93
$81.54
$3.94B-2.69769,133 shs350,752 shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$141.92
-0.7%
$108.75
$55.00
$177.37
$4.80B2.11.36 million shs674,766 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.00%+5.79%+5.08%-19.65%-18.04%
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
0.00%-7.09%-6.61%-15.01%+9.06%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.00%+4.82%+5.52%+59.48%+86.63%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
0.00%+2.75%+17.52%+111.08%+0.61%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
3.7233 of 5 stars
3.13.00.00.01.61.73.8
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.1156 of 5 stars
3.51.00.00.01.82.50.6
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
4.7558 of 5 stars
4.63.00.04.62.92.50.6
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.2949 of 5 stars
1.42.00.00.01.42.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
2.23
Hold$15.5427.13% Upside
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
3.00
Buy$31.1739.99% Upside
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3.11
Buy$106.7836.62% Upside
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.80
Moderate Buy$125.11-11.85% Downside

Current Analyst Ratings Breakdown

Latest BLFS, BLCO, TMDX, and SLNO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$19.00 ➝ $16.00
6/4/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$125.00 ➝ $145.00
6/3/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/13/2025
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/9/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$125.00 ➝ $130.00
5/9/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$105.00 ➝ $125.00
5/8/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$81.00 ➝ $97.00
5/8/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$102.00 ➝ $105.00
5/6/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$18.00 ➝ $12.00
5/2/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $15.00
5/1/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $13.00
(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$4.83B0.90$1.45 per share8.41$18.57 per share0.66
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$87.76M12.05N/AN/A$7.67 per share2.90
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/A$5.16 per shareN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$488.23M9.83$0.27 per share530.08$4.20 per share33.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
-$317M-$1.03N/A12.730.85-6.62%3.35%1.66%7/30/2025 (Estimated)
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$66.43M-$0.29N/AN/AN/A-38.98%-6.61%-5.54%8/14/2025 (Estimated)
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$38.99M-$4.62N/AN/AN/AN/A-61.99%-55.21%8/6/2025 (Estimated)
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$25.03M$1.36150.9899.25N/A8.14%18.74%4.39%7/30/2025 (Estimated)

Latest BLFS, BLCO, TMDX, and SLNO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$0.03$0.04+$0.07-$0.01$22.22 million$23.94 million
5/8/2025Q1 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.29$0.70+$0.41$0.70$123.39 million$143.54 million
5/7/2025Q1 2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$1.14-$0.95+$0.19-$0.95N/AN/A
4/30/2025Q1 2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$0.03-$0.07-$0.10-$0.60$1.15 billion$1.15 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
N/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.72
1.60
1.01
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
0.03
2.78
1.78
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/A
17.26
17.26
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.42
8.20
7.33

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
11.07%
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
93.24%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.76%
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.20%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
6.40%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
7.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
12,500353.72 million351.94 millionOptionable
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
44047.50 million45.37 millionOptionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3050.39 million37.81 millionOptionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
21033.82 million31.21 millionOptionable

Recent News About These Companies

Price Over Earnings Overview: TransMedics Group
These 24 Stocks Are Ripe for a Short Squeeze
TransMedics Group, Inc. (TMDX): A Bull Case Theory
TransMedics Group, Inc. (TMDX): A Bull Case Theory

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$12.22 -0.11 (-0.85%)
Closing price 03:58 PM Eastern
Extended Trading
$12.20 -0.03 (-0.20%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

BioLife Solutions stock logo

BioLife Solutions NASDAQ:BLFS

$22.26 +0.23 (+1.06%)
Closing price 03:59 PM Eastern
Extended Trading
$22.27 +0.01 (+0.03%)
As of 04:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Soleno Therapeutics stock logo

Soleno Therapeutics NASDAQ:SLNO

$78.16 -1.00 (-1.26%)
Closing price 03:59 PM Eastern
Extended Trading
$78.16 +0.00 (+0.01%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

TransMedics Group stock logo

TransMedics Group NASDAQ:TMDX

$141.92 -0.96 (-0.67%)
Closing price 03:59 PM Eastern
Extended Trading
$141.93 +0.00 (+0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.